ArticleOpen forum infectious diseases2020
Enhanced Surveillance for Histoplasmosis-9 States, 2018-2019.
Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 38 citations in OpenAlex.
- Histoplasmosis in kidney transplant recipients.BMC nephrology · 2026Review
- Misdiagnosis and Coinfection of Localized Pulmonary Histoplasmosis with Pulmonary Tuberculosis: A Systematic Review of Published Cases.Journal of fungi (Basel, Switzerland) · 2026Review
- Blastomycosis, Histoplasmosis, and Coccidioidomycosis in Outpatient Community-Acquired Pneumonia.JAMA network open · 2026Article
- Histoplasmosis with mediastinal lymphadenopathy in an immunocompetent municipal water department employee in Texas: a case report.Frontiers in cellular and infection microbiology · 2026Article
- Impact of Delays in Diagnosis on Healthcare Costs Associated With Blastomycosis, Coccidioidomycosis, and Histoplasmosis in a Commercially Insured Population.Open forum infectious diseases · 2025Article
- Cave-Associated Histoplasmosis Outbreak Among Travelers Returning from Costa Rica - Georgia, Texas, and Washington, December 2024-January 2025.MMWR. Morbidity and mortality weekly report · 2025Article
- Evolving Epidemiology, Improving Diagnostic Tests and Their Importance for the Correct Diagnosis of Histoplasmosis.Journal of fungi (Basel, Switzerland) · 2025Review
- Associations between Minority Health Social Vulnerability Index Scores, Rurality, and Histoplasmosis Incidence, 8 US States.Emerging infectious diseases · 2024Article
- Testing for Blastomycosis, Coccidioidomycosis, and Histoplasmosis at a Major Commercial Laboratory, United States, 2019-2024.Open forum infectious diseases · 2024Article
- Improving disseminated histoplasmosis diagnosis in HIV/AIDS patients in Suriname: The role of a urine lateral flow assay.PLoS neglected tropical diseases · 2024Article
- Histoplasmosis Beyond Human Immunodeficiency Virus (HIV): Clinical Characteristics and Outcomes in a Non-HIV Population.Open forum infectious diseases · 2024Article
- Histoplasmosis in Solid Organ Transplantation.Journal of fungi (Basel, Switzerland) · 2024Review
- Progressive disseminated histoplasmosis: The experience in one non-endemic medical center.Medical mycology · 2023Article
- The seroprevalence of anti-Histoplasma capsulatum IgG antibody among pulmonary tuberculosis patients in seven referral tuberculosis hospitals in Indonesia.PLoS neglected tropical diseases · 2023Article
- A Phylogeographic Description ofJournal of fungi (Basel, Switzerland) · 2023Article
- Public Health Research Priorities for Fungal Diseases: A Multidisciplinary Approach to Save Lives.Journal of fungi (Basel, Switzerland) · 2023Review
- Factors related to mortality in critically ill histoplasmosis: a multicenter retrospective study in Guadeloupe and French Guyana.Annals of intensive care · 2023Article
- Fungal Pathogens as Causes of Acute Respiratory Illness in Hospitalized Veterans: Frequency of Fungal Positive Test Results Using Rapid Immunodiagnostic Assays.Journal of fungi (Basel, Switzerland) · 2023Article
- Demographic and Socioeconomic Factors Associated with Fungal Infection Risk, United States, 2019.Emerging infectious diseases · 2022Review
- Surveillance for Coccidioidomycosis, Histoplasmosis, and Blastomycosis - United States, 2019.Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHistoplasmosis is often described as the most common endemic mycosis in the United States, but much remains unknown about its epidemiology among the general population.
methodsWe conducted enhanced surveillance in 9 states during 2018-2019 by identifying cases through routine surveillance and interviewing 301 patients about their clinical features and exposures.
resultsBefore being tested for histoplasmosis, 60% saw a health care provider ≥3 times, and 53% received antibacterial medication. The median time from seeking health care to diagnosis (range) was 23 (0-269) days. Forty-nine percent were hospitalized, and 69% said that histoplasmosis interfered with their daily activities (median [range], 56 [2-3960] days). Possible exposures included handling plants (48%) and bird or bat droppings (24%); 22% reported no specific exposures. Only 15% had heard of histoplasmosis before their illness.
conclusionsHistoplasmosis can be severe and prolonged. Additional educational efforts to increase public and provider awareness and reduce delays in diagnosis are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.